Insights

Innovative Therapies Call for an Integrated Drug Safety and Compliance Model

In this article, Herbert Lee, PharmD, Senior Vice President, Medical Communications and Pharmacovigilance, makes the case for an integrated approach to ensuring the safe and effective use of medications by patients. From emerging therapies to innovative…

Articles

IM4US
EVERSANA Presents “Advancing Patient Outcomes and Optimized Adherence” at IM4US

EVERSANA presents at the 9th annual IM4US (Integrative Medicine for the Underserved) conference: Solidarity and Self Care – Supporting Social Justice and Balance in Integrative Care.  The presentation, on Saturday, August 24 from 3:00-4:00pm, is titled,…

Top-100-canva
EVERSANA, Patient Experience Project featured in MM&M July Issue

Each year, Medical Marketing & Media compiles a list of the top 100 medical marketing agencies in North America. As MM&M Editor Stephen Madden shares at the opening of the July issue, “A typical issue of…

Power in numbers: Seven national plans manage almost half of the medical lives in the U.S.

Market Access Macrotrends provides  insight for you to stay on top of market access trends, anticipate how the healthcare landscape is evolving, and provide strategic guidance for your organization. Market Access Macrotrends answers your questions about changes in…

Streamline Chargeback and Channel Operations

Robert Blank, Managing Consultant at EVERSANA, moderated a panel with industry experts from Sanofi, Zydus, and UCB at CBI’s 15th Annual Commercial Contract and Chargeback Excellence.  The topic: “Process Improvement in Contract Administration and Management —…

no-image
Membership Management Challenges and Best Practices

In the pharmaceutical industry, access to pricing is primarily driven by membership.Institutions like hospitals, clinics, and pharmacies sign up as members of a Group Purchasing Organization (GPO) to be eligible to purchase products at a discounted…

no-image
Pharmaceutical Contracting from Volume to Value

Driven by skyrocketing costs, market forces are hastening the shift in the healthcare industry from volume based care (fee for service) to a value based reimbursement structure (fee for value). While the inertia of entrenched policies,…

white paper-insights
Medicaid Drug Classification: Civil Monetary Penalties

On April 18, 2019, the “Medicaid Services Investment and Accountability Act of 2019” was signed into law, bringing with it a significant change to the oversight and management of the Medicaid Drug Rebate Program (MDRP). Effective…

no-image
Gene Therapy for Rare Disorders

With only three approved products in the marketplace, how do we build a regenerative medicine ecosystem that delivers more value to patient’s faster?

white paper-insights
Setting a Patient Engagement Framework and Proving Value

Is your culture patient-centric? It needs to be because today’s patients are motivated information seekers – empowered decision-makers with respect to their treatment. Their voice is key to your success.

no-image
Insights from AMCP 2019

EVERSANA attended (and sponsored) The Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting. If you missed the conference, here are a few key takeaways from our colleagues who attended: 1) Federal and…